Switch theme
Sign up to access all valuation multiples
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
2012
10
LTM Revenue $0.6M
LTM EBITDA n/a
$24.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RenovoRx has a last 12-month revenue of $0.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, RenovoRx achieved revenue of $43K and an EBITDA of -$11.0M.
RenovoRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RenovoRx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $43K | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$11.4M | -$11.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -25512% | XXX | XXX | XXX |
| Net Profit | -$9.9M | -$10.2M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -23795% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, RenovoRx's stock price is $1.
RenovoRx has current market cap of $30.9M, and EV of $24.0M.
See RenovoRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.0M | $30.9M | XXX | XXX | XXX | XXX | $-0.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, RenovoRx has market cap of $30.9M and EV of $24.0M.
RenovoRx's trades at 38.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate RenovoRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for RenovoRx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $24.0M | XXX | XXX | XXX |
| EV/Revenue | 558.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | -3.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRenovoRx's NTM/LTM revenue growth is 409%
RenovoRx's revenue per employee for the last fiscal year averaged $4K, while opex per employee averaged $1.1M for the same period.
Over next 12 months, RenovoRx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate RenovoRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for RenovoRx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -25512% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -25103% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $4K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11600% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14012% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25612% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RenovoRx acquired XXX companies to date.
Last acquisition by RenovoRx was XXXXXXXX, XXXXX XXXXX XXXXXX . RenovoRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was RenovoRx founded? | RenovoRx was founded in 2012. |
| Where is RenovoRx headquartered? | RenovoRx is headquartered in United States of America. |
| How many employees does RenovoRx have? | As of today, RenovoRx has 10 employees. |
| Who is the CEO of RenovoRx? | RenovoRx's CEO is Mr. Shaun R. Bagai. |
| Is RenovoRx publicy listed? | Yes, RenovoRx is a public company listed on NAS. |
| What is the stock symbol of RenovoRx? | RenovoRx trades under RNXT ticker. |
| When did RenovoRx go public? | RenovoRx went public in 2021. |
| Who are competitors of RenovoRx? | Similar companies to RenovoRx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of RenovoRx? | RenovoRx's current market cap is $30.9M |
| What is the current revenue of RenovoRx? | RenovoRx's last 12-month revenue is $0.6M. |
| What is the current EV/Revenue multiple of RenovoRx? | Current revenue multiple of RenovoRx is 38.7x. |
| Is RenovoRx profitable? | Yes, RenovoRx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
